ImmunityBio (IBRX) EV to EBITDA (2015 - 2026)
Powered by 
Analysis
ImmunityBio (IBRX) EV to EBITDA (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn |
| 10 | ImmunityBio | 8.48 Bn | 8.12 Bn | 50.94 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -143.76 |
| Mar 31, 2026 | -109.66 |
| Dec 31, 2025 | -27.23 |
| Sep 30, 2025 | -38.94 |
| Jun 30, 2025 | -31.77 |
| Mar 31, 2025 | -38.94 |
| Dec 31, 2024 | -23.58 |
| Sep 30, 2024 | -30.69 |
| Jun 30, 2024 | -41.83 |
| Mar 31, 2024 | -36.41 |
| Dec 31, 2023 | -26.79 |
| Sep 30, 2023 | -8.16 |
| Jun 30, 2023 | -13.81 |
| Mar 31, 2023 | -6.03 |
| Dec 31, 2022 | -23.88 |
| Sep 30, 2022 | -20.66 |
| Jun 30, 2022 | -17.53 |
| Mar 31, 2022 | -21.24 |
| Dec 31, 2021 | -26.49 |
| Sep 30, 2021 | -47.70 |